YD Bio (YDESW) Shares Outstanding (2024 - 2026)
YD Bio's (YDESW) quarterly Shares Outstanding (Entity) came in at $70.8 million in Q4 2025, up 9.36% year-over-year from $64.7 million in Q4 2024, and up 9.36% quarter-over-quarter from $64.7 million in Q4 2024.
Powered by 
Analysis
YD Bio (YDESW) Shares Outstanding (2024 - 2026) Analysis & Trends
YD Bio (YDESW) has reported Shares Outstanding (Entity) for 2 consecutive years, with $70.8 million the latest figure, recorded in Q4 2025.
- On a quarterly basis, Shares Outstanding (Entity) rose 9.36% year-over-year to $70.8 million in Q4 2025; TTM through Dec 2025 was $70.8 million, a 9.36% increase from a year earlier, with the FY2025 full-year figure at $70.8 million, up 9.36% from the prior year.
- Shares Outstanding (Entity) was $70.8 million for Q4 2025 at YD Bio, up from $64.7 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $70.8 million in Q4 2025 and troughed at $64.7 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.68 Bn | 197.69 Bn | 7.24 Bn | 540.00 Mn |
| 2 | Gilead Sciences | 180.84 Bn | 177.66 Bn | 6.22 Bn | 1.24 Bn |
| 3 | Vertex Pharmaceuticals | 132.30 Bn | 124.45 Bn | 2.84 Bn | 253.70 Mn |
| 4 | Regeneron Pharmaceuticals | 82.50 Bn | 74.50 Bn | 3.93 Bn | 102.80 Mn |
| 5 | Argenx Se | 61.49 Bn | 56.31 Bn | 1.37 Bn | 61.30 Mn |
| 6 | Moderna | 55.01 Bn | 49.87 Bn | 52.00 Mn | 398.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.08 Bn | 30.77 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Biogen | 31.35 Bn | 30.06 Bn | 1.96 Bn | 147.70 Mn |
| 9 | Roivant Sciences | 29.87 Bn | 29.87 Bn | 1.16 Mn | 720.78 Mn |
| 10 | YD Bio | 29.02 Mn | 26.36 Mn | - | 66.72 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 66.72 Mn |
| Dec 31, 2025 | 66.72 Mn |
| Jun 30, 2025 | 64.73 Mn |
| Dec 31, 2024 | 64.73 Mn |